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Background: The goal of this study was to perform candidate gene association with cytotoxicity of
chemotherapeutics in cell line models through resequencing and discovery of rare and low frequency variants
along with common variations. Here, an association study of cytotoxicity response to 30 FDA approved drugs
was conducted and we applied next generation targeted sequencing technology to discover variants from 103
candidate genes in 95 lymphoblastoid cell lines from 14 CEPH pedigrees. In this article, we called variants across
95 cell lines and performed association analysis for cytotoxic response using the Family Based Association Testing
method and software.
Results: We called 2281 variable SNP genotypes across the 103 genes for these cell lines and identified three genes
of significant association within this marker set. Specifically, ATP-binding cassette, sub-family C, member 5 (ABCC5),
metallothionein 1A (MT1A) and NAD(P)H dehydrogenase quinone1 (NQO1) were significantly associated with
oxaliplatin drug response. The significant SNP on NQO1 (rs1800566) has been linked with poor survival rates in
patients with non-small cell lung cancer treated with cisplatin (which belongs to the same class of drugs as
oxaliplatin). A SNP (rs1846692) near the 5′ region of MT1A was associated with arsenic trioxide.
Conclusions: The results from this study are promising and this serves as a proof-of-principle demonstration of the
use of sequencing data in the cytotoxicity models of human cell lines. With increased sample sizes, such studies will
be a fast and powerful way to associate common and rare variants with drug response; while overcoming the cost
and time limitations to recruit cohorts for association study.
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Candidate geneBackground
There is increasing evidence that genetic variation can
explain some inter-individual variation in efficacy and
toxicity across a spectrum of drugs used for treatment of
various diseases. In situations where genetic factors dic-
tate or at least predict drug response, individualized
therapy holds a lot of promise and has already shown
success in drug choice and dosing [1]. A lot of these in-
fluential genetic factors have been identified in genetic* Correspondence: motsinger@stat.ncsu.edu
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unless otherwise stated.association studies nested within clinical trials, but these
studies are generally difficult to conduct with high power
due to difficulty in cohort recruitment, sample size limi-
tations, phenotype characterization, time and cost fac-
tors, etc. [2,3].
An alternate approach that has recently emerged to con-
ducting candidate gene studies in clinical subjects is to use
well-established cell lines (e.g. lymphoblastoid cell lines
(LCL)). Drug phenotyping is done on these cell lines, and
natural genetic variation in these cell lines is tested for asso-
ciation in a discovery phase. Of course the use of cell line
based model has its own limitations too – phenotypes may
not completely reflect observed human phenotypes, not allLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 List of 30 drugs used in this study
Drug Class
Busulfan Alkyl sulfonate
Mitoxantrone Anthracenediones
Daunorubicin Anthracyclines
Doxorubicin Anthracyclines
Epirubicin Anthracyclines
Idarubicin Anthracyclines
Topotecan Camptotheca
Hydroxyurea deoxyribonucleotide
Trichostatin A histone deacetylase inhibitor
Rapamycin mTOR inhibitor
Carboplatin Platinum
Oxaliplatin Platinum
Etoposide Podophyllum
Teniposide Podophyllum
Cladribine Purine
Fludarabine Purine
5-fluorouracil Pyrimidine
Azacitidine Pyrimidine
Cytarabine Pyrimidine
Floxuridine Pyrimidine
Gemcitabine Pyrimidine
Bleomycin Streptomyces
Mitomycin Streptomyces
Docetaxel Taxane
Paclitaxel Taxane
Temozolomide Triazines
Vinblastine Vinca alkaloid
Vincristine Vinca alkaloid
Vinorelbine Vinca alkaloid
Arsenic trioxide Other
The drugs and their chemical structure/functional class are listed.
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the cell line and the choice of cell line for a study may bias
the results. Despite these limitations, there are a large num-
ber of studies that have demonstrated that the LCL model
can be an effective and efficient way to identify new poten-
tial drug-response associated genes. For a review of cell line
models in pharmacogenomics, including a full discussion of
their advantages, disadvantages, and successes, see [4].
Recent LCL studies have shown that this model can be
used to estimate heritability of dose response [5], and it has
been used to recapitulate known drug response genes [6].
These previous studies have been performed using sin-
gle nucleotide polymorphisms (SNPs). To our know-
ledge, such mapping has never been performed using
next generation sequencing. In the current study, we use
next generation sequencing in a candidate gene ap-
proach to perform an association study of cytotoxic re-
sponse for 30 chemotherapy drugs. Response to each of
these drugs had previously been shown to have a heri-
table component [5], motivating the association mapping
performed in the current study. We used a candidate
gene approach, with more than 100 candidate genes that
were targeted for sequencing in 95 lymphoblastoid cell
lines derived from the Centre d’Etude du Poly-
morphisme Humain (CEPH) population [7]. These cell
lines were derived from individuals from 14 pedigrees.
Because the individuals were from related pedigrees,
family based association testing was performed via the
FBAT software [8]. After a multiple hypothesis correc-
tion was applied to each drug phenotype independently,
we found statistically significant hits for two drugs (oxa-
liplatin and arsenic trioxide) and some of the significant
markers identified in this study have been previously im-
plicated with drug response. This study demonstrates
the potential of using resequencing in cell-line cyto-
toxicity models of drug response, and proposed new can-
didate genes that may be associated with drug response.
Results and discussion
After variant calling was performed after a careful calling
pipeline and series of quality control screens, a total of
2281 SNPs were called across all samples. Of those 2281
SNPs, 904 (39.6%) are low frequency SNPs – they were
found in less than 5% of the samples used in this study.
A majority of these SNPs are intronic (46.9%), 20.24%
are exonic, and 18.8% are present in UTR. The
remaining 14.06% of SNPs did not have a transcript def-
inition associated with them for annotation. All the 2281
SNPs were tested for association with the dose response
phenotypes derived from cytotoxicity experiments for 30
drugs, where the phenotype used for association analysis
was a measure of cell viability after treatment with dif-
ferent doses of each of the 30 drugs. The drugs evalu-
ated are listed in Table 1. The 2281 SNPs were tested forassociation using the Family Based Association Testing
(FBAT) analysis tools, and an FDR correction for each
drug was performed such that q = 0.05 was used to
ascribe significance [9].
Our results show that two drugs - Arsenic Trioxide and
Oxaliplatin - had statistically significant hits after control-
ling for multiple testing. A Manhattan plot for the asso-
ciation results for Oxaliplatin is shown in Figure 1.
Manhattan plots for all association results across the candi-
date genes for all 30 drugs are shown in Additional file 1:
Figure S1. Details of the significant SNPs can be found
in Table 2.
There was a single SNP associated with Arsenic Tri-
oxide response. This SNP (rs1846692) is a known SNP,
and is upstream of the gene metallothionein (MT1A) on
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Figure 1 Manhattan plot for association with oxaliplatin. Manhattan plot for oxaliplatin is shown. The markers in black are significantly
associated at a FDR corrected threshold of 0.05.
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in strong linkage disequilibrium with variants in that
gene, as shown in Figure 2.
A total of 19 SNPs were significantly associated with
Oxaliplatin response. Of those 19, 6 SNPs are dispersed
in introns, exons and near the 5′ region of the gene
MT1A. Another 11 SNPs are in the untranslated region
(UTR3), intronic and exonic regions of the gene ATP-
binding cassette, sub-family C, member 5 (ABCC5/
MRP5) on chromosome 3, and the remaining 2 SNPs
are in the gene NAD(P)H dehydrogenase, quinone1
(NQO1) gene on chromosome 16. Linkage disequilib-
rium patterns across these genes are shown in Figures 3
and 4.
These gene associations represent interesting potential
drug response genes. ABCC5 belongs to the class of ATP-
binding cassette transporters and is involved in cellular
transport of cyclic nucleotides [10]. ABCC5 has previously
been associated with oxaliplatin resistance [11] and other
platinum drugs [12]; although the role of ABCC5 in drug
resistance is not clear [13]. In addition to ABCC5, variants
in NQO1 including a non-synonymous variant (rs1800566)
were associated with oxaliplatin. NQO1 is a member of
the platinum pathway and is involved in metabolism ofplatinum based drugs. NQO1 has been linked with resist-
ance to another platinum containing drug cisplatin [14-16]
and may share a common role with metabolism of oxalipla-
tin. This reaffirms the potential of the model to detect cli-
nically meaningful associations, making us more optimistic
about the potential relevance of the other findings. While
the nature of any candidate gene study is that the genes
chosen have biological relevance to the trait of interest, it is
important to note that since the candidates were chosen
across all 30 drugs in the current study, there is ample
opportunity to discover novel associations.
Variants in the metallothionein 1A (MT1A gene) were
significantly associated with both Oxaliplatin and Ar-
senic Trioxide. This respresents a novel association with
these two drugs to the best of our knowledge. MT1A has
been previously shown to be associated with cisplatin
resistance [17], but it is not known how this relates to
Oxaliplatin and Arsenic Trioxide. We did look up ex-
pressions quantitative trait loc (eQTL)status for these
SNPs using NCBI’s Phenotype-Genotype Integrator
(PheGenI) database, and none of this significant SNPs
were in known eQTL regions [18]. These associations
should be followed up in future studies, in both func-
tional experiments and clinical samples.
Table 2 Significant hits from association
Drug(s) SNP ID SNP position Gene q-value MAF
Arsenic Trioxide rs60900828 (A/T) Chr16:56671632 MT1A (near-gene 5) 0.047628 0.138
Oxaliplatin rs562 (C/T) Chr3:183637845 ABCC5 (UTR3) 0.049494 0.392
rs3749445 (A/G) Chr3:183638506 ABCC5 (UTR3) 0.044895 0.410
rs2292998 (C/T) Chr3:183663833 ABCC5 (intronic) 0.039882 0.277
rs1016752 (C/G) Chr3:183665062 ABCC5 (intronic) 0.039781 0.232
rs4148585 (C/T) Chr3:183670642 ABCC5 (intronic) 0.039781 0.283
rs6443924 (A/G) Chr3:183679532 ABCC5 (intronic) 0.039781 0.279
rs4148579 (A/G) Chr3:183685249 ABCC5 (intronic) 0.039781 0.279
rs939336 (A/G => C594C) Chr3:183685534 ABCC5 (exonic) 0.039781 0.279
rs1132776 (C/T => A395A) Chr3:183696402 ABCC5 (exonic) 0.044895 0.289
rs2313212 (C/T) Chr3:183700928 ABCC5 (intronic) 0.039781 0.279
rs4148575 (C/T) Chr3:183702275 ABCC5 (UTR3) 0.044895 0.289
rs1846692 (C/T) Chr16:56671696 MT1A (near - gene 5) 0.049494 0.360
rs35346959 (A/G) Chr16:56671867 MT1A (near- gene 5) 0.044895 0.137
rs9922957 (C/G) Chr16:56672380 MT1A (near - gene 5) 0.039781 0.185
rs9922409 (A/G) Chr16:56672400 MT1A (near - gene 5) 0.04532 0.103
rs7190725 (G/T) Chr16:56673290 MT1A (intronic) 0.044895 0.170
rs8052394 (A/G => K51R) Chr16:56673828 MT1A (missense) 0.044895 0.152
rs1800566 (C/T => P187S) chr16:69745145 NQO1 (exonic) 0.039781 0.258
rs689455 (A/C) Chr16:69761661 NQO1 (near- gene 5) 0.039781 0.242
Significant hits from association at FDR corrected threshold of 0.05 are shown in this table. All hits are known dbSNP common variants. All data is reported from
Database of Single Nucleotide Polymorphisms (build 137).
Figure 2 Linkage disequilibrium plot for MT1A. Markers significantly associated with Oxaliplatin are highlighted with black boxes and the one
associated with Arsenic Trioxide is marked with a red box.
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Figure 3 Linkage disequilibrium plot for markers in ABCC5: Markers significantly associated with oxaliplatin are highlighted with
black boxes.
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This study selected 14 CEPH LCL pedigrees to perform
association analysis of 103 candidate genes to drug re-
sponse for 30 chemotherapeutics. The 103 candidate re-
gions were sequenced with sufficient depth to determine
variants within each LCL. Sequencing data allowed us to
have a higher resolution for the markers called than
genotyping data from standard genotyping chips would
have allowed. The added benefit of detecting more vari-
ants than offered by a genotyping chip comes at the cost
of time required to set up the pipeline for variant calling
(even with open source software), computational time,
space and resources required to process each sample
and data management. Approximately 2.5TB of data
generated from this sequencing study (including raw
FASTQs, processed FASTQs, intermediate alignment
files, and variant call files) allowed us to call 2281 vari-
able genotypes across the 94 samples.
We conducted FBAT for all the markers discovered in
this study for 30 drug response phenotypes. When ac-
counting for all markers and drugs, no hits are signifi-
cant after an FDR correction. This is not surprising and
the loss of power to detect any significant association
can be attributed to the small sample size used in thisstudy and a heavy burden of multiple hypotheses testing
correction (for 30 drug phenotypes). However, when we
do not apply correction for phenotypes but only correct
for multiple markers per drug, we observe significant
hits for 2 drugs at FDR corrected threshold of 0.05.
While our correction strategy is not strictly conservative,
we feel that it is appropriate given the exploratory/
hypothesis-generation goals of the study.
Only 2 of 30 drugs showed significant hits and no
SNPs in known drug metabolizing enzymes were signifi-
cantly associated with our trait of interest. It is quite
possible that none of the markers in these genes had a
big enough effect size for other drugs to be easily de-
tected in this study. Also, it is well known that drug re-
sponse is a complex phenotype and SNP interactions
may be able to explain some of the observed variability
in drug response; but they were not tested in this study.
There is a possibility that mechanisms other than poly-
morphisms in genes may have an influence on drug
phenotype (e.g. miRNA, transcript expression). In con-
clusion, while the small sample size limits the inference
that can be made in the current data, this study is a
proof-of-principle demonstration of the use of sequen-
cing data in the cytotoxicity models of human cell lines,
Figure 4 Linkage disequilibrium plot for markers in NQO1: Markers significantly associated with oxaliplatin are highlighted with
black boxes.
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be further investigated in future studies. As sequencing
data becomes more accessible, such an approach will
likely be more commonly applied to associate rare and
novel variants alongside common variants with drug
response that would have otherwise been missed by
GWAS chips.
Methods
Cytotoxicity phenotypes
The cytotoxicity data from Peters et al. were used as the
phenotypes for association analysis. Briefly, 125 lympho-
blastoid cell lines from 14 CEPH families were treated
with four doses of each of 30 chemotherapy drugs (A list
of drugs used in this study is available in Table 1) to cap-
ture the linear portion of the cell kill curve. Cell viability
was used as a measure for drug induced cytotoxicity -
higher cytotoxicity would result in lower cell viability in-
dicating better drug response; whereas lower cytotoxicity
would account to higher cell viability implying poor drug
response. The cell viability was quantified using the
non-toxic Almar Blue reagent which is converted into a
fluorescent compound by the living cells. The fluores-
cence of drug treated cells was measured relative to cells
treated with vehicle control (DMSO) to account forbackground noise. Outliers were removed and one aver-
age measurement across replicates was used for any fur-
ther analysis. Drug response measured via cell viability
was used as the phenotype in our association study. De-
tails of the phenotyping experiments can be found in [5].
Details of the quality control measures used can be
found in [19]. Most of the drugs tested showed an esti-
mated heritability of 0.3 or greater in the Peters et al.
study [5] indicating that the genetic component explains
a significant amount of variability in drug response.
Selection of cell lines for sequencing
Of the four drug concentrations for each antitumor agent,
the one that resulted in an average viability closest to 50%
across all cell lines was used for determining sensitivity or
resistance to that agent. Cell lines demonstrating extreme
responses, defined as viability below the 10th or above the
90th percentiles of the viability distribution at the selected
dose for a given drug, were respectively labeled as sensitive
and resistant to that drug. Ninety-five CEPH cell lines that
displayed sensitivity and/or resistance to at least one of 23
drugs were selected for candidate gene sequencing. The 23
drugs upon which the selection criteria were based in-
cluded 14 drugs from one of 5 drug classes (fluoropyrimi-
dines, anthracyclines, platinum compounds, taxanes, and
Hariani et al. BMC Research Notes 2014, 7:360 Page 7 of 10
http://www.biomedcentral.com/1756-0500/7/360camptothecins), as well as an additional 9 drugs for which
the cytotoxicity profiles across the entire set of 125 cell lines
showed high correlation with those of the 14 targeted
drugs. A complete list of the 95 cell lines and pedigree
structure is available in Additional file 1: Table S1.
Candidate gene sequencing
103 candidate genes were selected for resequencing based
on their involvement in pathways for drug metabolism,
transport, or drug action for 5 classes of chemotherapy
drugs tested in the in vitro cytotoxicity assay described
above: fluoropyrimidines, anthracyclines, platinum com-
pounds, taxanes, and camptothecins. The candidate genes
selected are listed in Additional file 1: Table S2. A multiplex
PCR reagent for amplification of the exons, including un-
translated regions and approximately 1000 bp upstream of
the first exon, from all the candidate genes was designed by
RainDance Technology (RDT). This technology allows for
independent amplification of multiple PCR reactions in a
single tube through the sequestration of primer pairs for
each amplicon in separate, picoliter-volume microdroplets
[20]. A total of 1932 amplicons were designed to capture
the 103 candidate genes. The mean amplicon size was 514
bp (range 206-600 bp), and up to 18 amplicons were tiled
to cover large exons. The total amount of genomic DNA
sequence expected to be amplified by this PCR multiplex is
800,965 bp. After merging microdroplets containing
genomic DNA from each of the 95 cell lines with the multi-
plex, primer microdroplet mix on an RDT1000 microfluidic
station, samples were PCR amplified, amplicon DNA was
purified, ligated, randomly sheared, and used to prepare se-
quencing libraries. Libraries were sequenced on Illumina
Genome Analyzer II (GAIIx) sequencers to generate 36
base, single end sequences (i.e., only sequenced one end of
the read) using between one and 9 sequencing lanes per
sample, resulting in high depths and coverage across the
amplicons.
Pipeline for variant discovery
The sequencing data obtained from different centers was
subjected to rigorous data cleaning before variant call-
ing. We received data for all samples in FASTQ format.
A FASTQ is a standard file format to store sequence
and Phred scaled base quality information [21]. A Phred
quality score is the -10*log10(estimated probability that
the base was called incorrectly). Every FASTQ (141 for
95 samples) went through the following pipeline that
was developed at Expression Analysis Inc, and modified
for application to this dataset:
1. Adapter clipping and low quality base trimming:
Adapter clipping and read trimming was done using
fastq-mcf. Any adapter sequences from the ends of
the reads were clipped (adapters are known DNAsequences that allow the DNA molecule to attach to
the flowcell where the sequencing chemistry occurs).
Also, trailing low quality bases were trimmed from
the ends of the reads. Both these steps improve the
number of reads that can be mapped back to the
genome. FASTQ quality statistics such as nucleotide
distribution per cycle and base quality score per
cycle were computed to make certain that the se-
quencing runs had not failed at any cycle and the
FASTQs were of high quality.
2. Base Quality Score Recalibration: The Phred base
qualities provided by Illumina are known to be
inflated for higher quality values [22] and can be
corrected by incorporating the error rate from a
PhiX control run. A heuristic polynomial model
determined from the PhiX alignment data was used
to correct for the Illumina provided base quality
scores at the clipped FASTQ level. This was done
to ensure only high quality variants were called in
further analysis.
3. Read Alignment and pileup: Burrows-Wheeler
Alignment Tool (BWA) v0.5.9 [23] was used to align
reads to human genome (Hg19). Default parameters
were used for alignment and generation of the Se-
quence Alignment Map (SAM) files that contain
alignment coordinates and mapping qualities in a
standard format [24]. Statistics for the aligned files
were generated to gain an idea of the capture quality
by quantifying the number of reads mapped, map-
ping qualities, and percent alignment on different
chromosomes. The SAM files were then converted
to pileup formats using Samtools v0.1.15 [24] which
were consequently used for computing quality statis-
tics. Pileup format gives base-by-base information
for all aligned reads in terms of chromosomal pos-
ition, reference base, the number of reads aligned at
that position, base calls, and base qualities [24].
Rigorous quality statistics were computed using the
pileup format to assess the PCR and hybrid capture
processes. These quality checks include coverage,
depth, uniformity of coverage, number of bases that
fall inside of amplicons vs. outside of amplicons,
number of reads that fall within the amplicons vs.
outside of them (unpublished work, Expression
Analysis Inc, Durham), and total number of ampli-
cons captured.
4. Variant Calling: Prior to SNP calling, samples with
replicate runs were merged into one BAM file
(binary equivalent of SAM). Along with the merged
bam file, variant calling was conducted on each
replicate to allow for consistency check. The bam
files were then realigned around regions containing
insertions or deletions (indels) to minimize the
number of mismatch SNPs and false SNP calls and
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a secondary realignment around known dbSNP indel
regions (Available from: http://www.ncbi.nlm.nih.
gov/SNP/) was done, followed by variant calling.
The realignment and variant calling were done using
the open source JAVA software, Genome Analysis
Tool Kit (version 1.4-30-gf2ef8d1) (GATK) [25]
using the default parameters and all available depth
(no downsampling was carried out). Genotype calls
provided by GATK were used for association
analysis.
5. Variant Filtering: Due to the few number of variant
calls made in the candidate regions, the GATK
variant filtering could not be used; and custom
filters were set up to ensure that highest quality
variants passed through. SNPs meeting any of the
following criteria were masked to unknown
genotypes:
a. Quality By Depth (GATK parameter): <=2.5; This
is a GATK parameter which is computed as
phred scaled probability of observing a variant at
the given site/depth at the site. Low QD values
may indicate errors (Broad Institute, 2011)
b. Strand Bias (GATK parameter): > = 60; GATK
parameter where high values indicate that mostly
one of the strands is showing evidence for the
variant.
c. Depth: <=5
d. Known dbSNP indel was called within the
individual at this position
e. If any two of the following conditions were met,
the genotype calls were masked out:
i. The site under consideration was called with
multiple alleles in the given sample of 95
individuals
ii. Additional variant calls were made within a
few bases of the site in this individual or the
population (Possible indication of alignment
error or sequencing error of low complexity
region)
iii. The variant call was made within 3 bases to
the left of the sense primer or 3 bases to the
right of antisense primer
f. Mendelian rules of transmission were used to
rescue inaccurately called genotypes in offspring.
6. Variant Quality/Genotype Quality assessment:
Genotypes from samples were compared to available
Hapmap phase III sample calls (http://hapmap.ncbi.
nlm.nih.gov/). Genotypes across different replicates
in the candidate gene study were compared.
Genotype consistency was also determined by
Mendelian error checks. To compute Mendelian
error, a superset of variant positions was generated
for every nuclear family (trio) in a pedigree. For eachvariant position, if a variant call was not made in a
family member in presence of sufficient depth (20),
then a homozygous reference genotype was assigned
to that member. Variant Quality assessment was also
made in terms of dbSNP membership.
Association analysis
Family Based Association Testing (FBAT version 2.0.3)
software was used to test the null hypothesis of no link-
age or no association of marker with unknown trait
locus. The testing was conducted for autosomal markers
only (sex linked markers were not used in this study).
The minimum number of informative families was set to
4 in order to maximize the utilization of available
marker set. The offset value for each phenotype was set
to the sample mean of that phenotype because the phe-
notypes were relatively normal and no ascertainment
bias from extreme percentiles of cell viability distribu-
tion was observed.
Implementation
The pipeline for variant calling was implemented in bash
scripting. Variant filtering was done using custom R and
perl scripts. The pipeline was run on a cluster of 30 com-
modity servers with 4 to 24 CPUs per node, 8 to 60 GB of
RAM per node, and Ubuntu Linux as the operating system.
To process a single FASTQ with approximately 14M reads
for steps 1 – 3 on a single CPU with 40 GB of RAM re-
quired 2 hours and 45 min of CPU time. Alignment to the
human genome was the most time consuming step (~91
minutes).
FASTQ quality assessment
Due to processing of DNA samples at four sequencing
centers, we had 141 FASTQ files (FASTQs) generated
for 95 LCLs with each sample having between 1 to 9
FASTQs. The read lengths and number of reads per
FASTQ varied for different samples across centers. The
number of reads per FASTQ ranged from 16K to 29M
indicating cluster generation problems for certain flow-
cells. The low count read FASTQs were discarded from
any further analysis as an entire flowcell showed cluster
generation problems. We were left with 134 FASTQs for
the 95 samples.
SAM quality and Amplicon capture assessment
The FASTQs were processed and aligned to UCSC hg19
assembly using BWA software. For the candidate gene
study, 94.08% reads on average (±1.52% sd) aligned per
sample with a median mapping quality score of 37. Un-
surprisingly, samples with higher number of reads showed
higher coverage – more targeted amplicons were se-
quenced and at higher mean depths. The average depth
over all amplicons in a sample was 255.20 (±130.29 sd).
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at least 1X) varied from 85.40 – 99.79%. The high variability
in mean depth and coverage can be accounted to low read
counts from 3 different flowcells and variability in on-target
performance. On-target performance was assayed in terms
of percent bases on target vs. outside of targeted regions –
on average, 45.66% (±9.43 sd) of total sequenced bases
within a sample aligned to the targeted regions.
The uniformity of capture at a given depth was calcu-
lated for every amplicon per sample using a measure
called Area Under the Reference Line (AURL) (unpub-
lished work, Expression Analysis Inc, Durham), where
the reference line is defined by the depth under consid-
eration. For a uniform coverage at that depth, the AURL
will be close to 1; non-uniformity resulting from depths
lower than reference line reduces the value of AURL to-
wards zero. Overall, the mean AURL within a sample
was 94.80 and 92.95 at depths 20 and 30 respectively;
signifying that the amplicons within an individual were
uniformly covered at sufficient depth to call variants for
most positions. The samples that showed low AURLs
belonged to flowcells with low read counts. Given the
relatively low performance of these lanes; 15 replicate
samples were discarded from further analysis without
resulting in any data loss for the 95 LCLs.
Variant calling
The Genome Analysis Toolkit from BROAD Institute
was used for variant calling and filters described in
Methods section were set to retain high quality variants.
Additional file 1: Figure S1 summarizes Mendelian seg-
regation error rates for the trios generated from all pedi-
grees after SNP variant filtration. One of the family trio
(offspring 12142 from pedigree 1334) showed very high
Mendelian error rate even after filtering (40.82%) – indi-
cating that the sample might have been mislabeled and
was excluded from any further analysis. One other sam-
ple (NA12700) that showed high Mendelian error rate
before filtering was sequenced over nine lanes of flow-
cells and variants were called at extremely high depths
for this sample, but the error rate substantially reduced
(1.76%) after filtering of variants. The remaining trios
showed on an average 7.88 ± 4.63% error rates before fil-
tering and 0.87 ± 0.59% after filtering. Hapmap data was
available for 18 samples used in this study – this was
used to check genotype consistency from sequencing
data. Before filtering, an average of 96.41 ± 1.27% of vari-
ants in Hapmap were called in sequencing data with
matching genotypes and 99.79 ± 0.12% of homozygous
reference calls were called non-variant sites in sequen-
cing data. After filtering, an average of 95.32 ± 2.17% of
variants in Hapmap were called consistently in sequen-
cing data and 99.88 ± 0.08% of reference calls were called
non-variant in sequencing data (we improved specificityas the cost of sensitivity) (Additional file 1: Figure S2).
Variant quality was further assessed by looking at dbSNP
membership of the calls. Most of the filtered calls were
non-dbSNP members (Additional file 1: Figure S2). The
various quality assessments ensure that we were left with
2281 high quality SNPs in the targeted regions across
all cell lines for association analysis. Genotype calls
for >78% SNPs were available in 90 samples or more.
Additional file
Additional file 1: Supplementary tables and figures.
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